I break down DBS Group Research’s latest STI call and why the “earnings-driven” qualifier matters more than the 350-point upgrade. If multiples do the heavy lifting, your yield shrinks even as prices climb. If earnings grow, dividends have room to rise with the index. This episode shows income investors what to watch for the rest of 2026.
Key takeaways:
DBS lifted its STI year-end target to 5,850, up 350 points from 5,500
The STI is already trading near 16.7x forward earnings, about +2 standard deviations
Multiple expansion pushes prices up without lifting dividends, squeezing yield
Earnings-driven gains let payouts grow alongside prices, supporting yield
Watch FY2026/27 earnings revisions and dividend announcements, not just index levels
Iggy’s Forensic Disclaimer
This content is produced for educational and informational purposes only. I am not a financial advisor — I am a retail investor who applies forensic analysis to my own portfolio and shares that process publicly. Nothing here constitutes a recommendation to buy, sell, or hold any security, and no specific target prices or personalised financial advice are offered. Stocks assessed under Iggy’s Forensic Yield Standard are benchmarked against a 4.7% minimum yield hurdle; stocks flagged as Growth Watch fall below this threshold but demonstrate clean balance sheet metrics and an identifiable growth catalyst — these carry a materially different risk profile and are not suitable as yield replacements for income-dependent investors. All data is sourced from public filings and verified sources; where data is unverified it is explicitly flagged. All investments carry risk, including the potential loss of principal, and past performance is not indicative of future results. If you are making investment decisions involving CPF, SRS, or personal capital, please conduct your own due diligence or consult a MAS-licensed financial adviser before committing funds.
